Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C42H72O14 |
Molecular Weight | 801.0127 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 21 / 21 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]3([H])[C@@]4(C)CC[C@H](O)C(C)(C)[C@]4([H])[C@H](C[C@@]23C)O[C@]5([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@]6([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)[C@@](C)(O)CCC=C(C)C
InChI
InChIKey=UZIOUZHBUYLDHW-XUBRWZAZSA-N
InChI=1S/C42H72O14/c1-20(2)10-9-13-42(8,52)21-11-15-40(6)28(21)22(45)16-26-39(5)14-12-27(46)38(3,4)35(39)23(17-41(26,40)7)53-37-34(32(50)30(48)25(19-44)55-37)56-36-33(51)31(49)29(47)24(18-43)54-36/h10,21-37,43-52H,9,11-19H2,1-8H3/t21-,22+,23-,24+,25+,26+,27-,28-,29+,30+,31-,32-,33+,34+,35-,36-,37+,39+,40+,41+,42-/m0/s1
Molecular Formula | C42H72O14 |
Molecular Weight | 801.0127 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 21 / 21 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.root9ginseng.com/about-red-ginseng.html | https://www.ncbi.nlm.nih.gov/pubmed/26045687Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27224660
Sources: http://www.root9ginseng.com/about-red-ginseng.html | https://www.ncbi.nlm.nih.gov/pubmed/26045687
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27224660
Ginsenoside Rf has being shown to have the inhibitory effect on the inflammatory mediators downstream of p38/NF-kB activation on TNF-α-stimulated intestinal epithelial cells (HT-29) and mouse macrophage cells (RAW264.7). Ginsenoside Rf significantly reduced the production of IL-1β, IL-6, TNF-α, NO, and ROS, which are most highly activated in IBD. In addition, ginsenoside Rf significantly suppressed TNF-α/LPS-induced NF-κB transcriptional activity. Ginsenoside Rf has being shown to contains a compound that has potent intestinal anti-inflammatory effects that could be used to treat diseases such as IBD. Computational and experimental data suggest that Ginsenoside Rf may help attenuate obesity by interacting with PPARg and inhibiting adipogenesis. However, further studies in animal models will be required to assess the true potential of Rf as an antiobesity drug. Ginsenoside Rf is one of the major components of Korean Red Ginseng, marketed in Korea. Korean ginseng (Panax ginseng Meyer, Araliaceae) is traditionally used as an important herbal medicine in Far East Asia. Korean Red Ginseng is possibly effective for:
• Alzheimer's disease. Evidence shows that taking Panax ginseng root daily for 12 weeks can improve mental performance in people with Alzheimer's disease.
• Lung disease called chronic obstructive pulmonary disease (COPD). Taking Panax ginseng by mouth seems to improve lung function and some symptoms of COPD.
• Mental function. Taking Panax ginseng by mouth might improve abstract thinking, mental arithmetic skills, and reaction times in healthy, middle-aged people but not in young adults. Panax ginseng alone does not seem to improve memory. But there is some evidence that a combination of Panax ginseng and ginkgo leaf extract can improve memory in otherwise healthy people between the ages of 38 and 66.
• Erectile dysfunction (ED). Taking Panax ginseng by mouth seems to improve sexual function in men with erectile dysfunction.
• Flu. Taking a specific Panax ginseng by mouth appears to reduce the risk of getting a cold or the flu. But, taking Panax ginseng does not seem to reduce flu symptoms or the length of the illness.
• Multiple sclerosis-related fatigue. Taking Panax ginseng daily for 3 months reduces feelings of tiredness and improves quality of life in females with MS.
• Premature ejaculation. Applying a cream containing Panax ginseng, angelica root, Cistanches deserticola, Zanthoxyl species, torlidis seed, clover flower, asiasari root, cinnamon bark, and toad venom (SS Cream) to the penis one hour before intercourse and washing off immediately before intercourse seems to help prevent premature ejaculation.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0002532 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27224660 |
|||
Target ID: CHEMBL235 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26045687 |
|||
Target ID: CHEMBL614347 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24173574 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02204826
KRG extract contained 0.67mg/g Ginsenoside Rf, as well as ginsenoside-Rb1: 4.26mg/g, -B2: 1.71 mg/g, -Rc: 1.80mg/g, -Rd: 0.29mg/g, -C: 1.62 mg/g, -Rg1: 2.61mg/g, -Rg2: 0.20mg/g, -Rg3: 0.13mg/g, and other minor ginsenosides. During the study period, three capsules (500 mg/dose) were taken daily for 12 weeks
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26045687
Treatment with ginsenoside Rf at concentrations of 10 and 100 uM reduced the mRNA levels of PPARg by 8% and 52%, and the mRNA levels of perilipin by 14% and 65%, respectively, in 3T3-L1 adipocytes
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:52:59 GMT 2023
by
admin
on
Sat Dec 16 09:52:59 GMT 2023
|
Record UNII |
JOS8BON5YW
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
67986
Created by
admin on Sat Dec 16 09:53:00 GMT 2023 , Edited by admin on Sat Dec 16 09:53:00 GMT 2023
|
PRIMARY | |||
|
DTXSID90904205
Created by
admin on Sat Dec 16 09:53:00 GMT 2023 , Edited by admin on Sat Dec 16 09:53:00 GMT 2023
|
PRIMARY | |||
|
52286-58-5
Created by
admin on Sat Dec 16 09:53:00 GMT 2023 , Edited by admin on Sat Dec 16 09:53:00 GMT 2023
|
PRIMARY | |||
|
JOS8BON5YW
Created by
admin on Sat Dec 16 09:53:00 GMT 2023 , Edited by admin on Sat Dec 16 09:53:00 GMT 2023
|
PRIMARY | |||
|
441922
Created by
admin on Sat Dec 16 09:53:00 GMT 2023 , Edited by admin on Sat Dec 16 09:53:00 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
USP
|